Mineralys Therapeutics, Inc.Mineralys Therapeutics, Inc.Mineralys Therapeutics, Inc.

Mineralys Therapeutics, Inc.

No trades
See on Supercharts

Price target

32.570.000.00%
The 7 analysts offering 1 year price forecasts for MLYS have a max estimate of — and a min estimate of —.

Analyst rating

Based on 8 analysts giving stock ratings to MLYS in the past 3 months.

EPS

‪0.00‬
Reported
Estimate
Reported
Estimate
Surprise

Revenue

‪0.00‬
Reported
Estimate
Reported
Estimate
Surprise
Be warned

Frequently Asked Questions


MLYS EPS for the last quarter is −1.13 USD despite the estimation of −0.86 USD. In the next quarter EPS is expected to reach −1.04 USD. Track more of Mineralys Therapeutics, Inc. financials and stay on top of what is up with the company.
In the next quarter Mineralys Therapeutics, Inc. revenue is expected to reach 0.00 USD. Check out Mineralys Therapeutics, Inc. revenue and earnings and make informed decisions.
According to analysts, MLYS price target is 32.57 USD with a max estimate of 45.00 USD and a min estimate of 26.00 USD. Check if this forecast comes true in a year, meanwhile watch Mineralys Therapeutics, Inc. stock price chart and keep track of the current situation with MLYS news and stock market news.
We've gathered opinions of 8 analysts rating MLYS stock in the past 3 months. Most of them backed up the strong buy trend, and after taking into account other opinions, the overall rating was calculated as strong buy. Note that it's not a trading advice — your own analysis is still required.